A US Biosimilar Turning Point Approaches, With Work To Do
2022 will be an important year for biosimilar manufacturers as the market expands into new areas like ophthalmology and insulin, and as the Humira US biosimilar entry nears in 2023.
2022 will be an important year for biosimilar manufacturers as the market expands into new areas like ophthalmology and insulin, and as the Humira US biosimilar entry nears in 2023.